- Imprimis Pharmaceuticals (IMMY -4.7%) acquires the intellectual property, including a provisional patent application, related to an ophthalmic compound for intraoperative ocular injection of anti-inflammatory and anti-bacterial agents from Novel Drug Solutions.
- The target compound, referred to as IPI-140, is based on a combination of moxifloxacin and triamcinolone.
- IMMY says it believes the formulation has the potential to "impact the fast-growing $5B global cataract surgery drug market."
- Additionally, the deal gives IMMY preemptive rights to other Novel Drug Solutions and Eye Care Northwest intellectual property and drug development opportunities.
Imprimis Pharmaceuticals acquires the intellectual property rights for ophthalmic compound from Novel Drug Solutions
Aug 28 2013, 13:57 ET